BARDA Broad Agency Announcement for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures

This announcement is for the award of a Cost Plus Fixed Fee (CPFF) type Research and Development contract to CUBRC, Incorporated for the development of TP-434, a novel fluorocycline antibiotic of the tetracycline class for the treatment of select bacterial infections under the procedures of the subject Broad Agency Announcement (BAA).

This announcement is for the award of a Cost Plus Fixed Fee (CPFF) Research and Development contract to Southwest Research Institute (SwRI) for the advanced development of an amyl nitrite system for treatment against cyanide exposure under the procedures of the subject Broad Agency Announcement (BAA).

This announcement is for the award of a Cost Sharing Research and Development contract to GlaxoSmith Kline, LLC for the development of a novel boron-based inhibitor of bacterial leucyl-tRNA synthetase, an Antibiotic for the treatment of select bacterial infections under the procedures of the subject Broad Agency Announcement (BAA).

This announcement is for the award of a Cost Plus Fixed Fee (CPFF) Research and Development contract to SNBL Clinical Pharmacology Center, Incorporated (SNBL CPC) for the Label Comprehension Assessment of an Emergency Use Prototype Household Antibiotic Kit under the procedures of the subject Broad Agency Announcement (BAA).

This announcement is for the award of a Cost Plus Fixed Fee (CPFF) Research and Development contract to Chimerix Incorporated for the development of CMX001 under the procedures of the subject Broad Agency Announcement (BAA).

BARDA encourages the advanced research, development and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the threat of CBRN agents in support of the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) articulated in the PHEMCE Implementation Plan for CBRN Threats. The Implementation Plan is located on the ASPR website (http://www.hhs.gov/aspr/barda/phemce/index.html).



In addition, the Pandemic and All Hazard Preparedness Act (PAHPA) directs BARDA to promote (i) innovations in technologies that may assist countermeasure and product advanced research and development (ii) research on and development of research tools and other devices and technologies and (iii) research to promote strategic initiations. The PAHPA is located on the ASPR website http://www.hhs.gov/aspr/opsp/pahpa/index.html.



The purpose of this BAA is to solicit proposals that focus on one or more of the following areas of interest as listed here and further described in Part I.



Research Areas of Interest:

Vaccines Development

Antitoxins and Therapeutics

Antimicrobials and Antivirals

Radiological and Nuclear Agent Countermeasures

Chemical Agent Countermeasures

Diagnostics



BARDA anticipates that research and development activities awarded from this Broad Agency Announcement (BAA) will serve to advance the knowledge and scientific understanding of candidates countermeasures for CBRN threats toward eventual FDA approval and their inclusion in the Strategic National Stockpile (SNS).



The Government intends to have a full & open competition for this requirement in the form of a BAA. This synopsis is not a BAA; a BAA is anticipated on March 3, 2010. The Government expects to make 1 or more awards, subject to the availability of funds, on or about September 16, 2010.





Point of Contact:



Comments to this announcement, referencing synopsis BARDACBRN BAA-10-100-SOL-00012 may be submitted to Glynis Fisher, Contracting Officer at 202-260-1880 or in writing to glynis.fisher@hhs.gov.



Pre-proposal Conference:



A pre-proposal conference will be held on March 26, 2010 from 2-4 pm at the following address:



200 Independence Avenue S.W.

Hubert H Humphrey Building 5th floor Room 505A

Washington, DC 20201



Please note the following regarding the pre-proposal conference:

1. Enter the Humphrey Building at the Independence Avenue Street entrance.

2. Arrive 30 minutes early to allow time to clear security.

3. Bring your identification

4. The closest metro stop is Federal Center SW

5. Attendance is limited to a maximum of two (2) people per company. Email the names of your attendees to glynis.fisher@hhs.gov by Friday, March 12, 2010.

6. Tape recorders and videos are prohibited.

7. Presentation material from the conference will be posted on FedBizOpps in an amendment to the BAA following the pre-proposal conference



Pre-proposal Conference #2: A second pre-proposal conference will be announced in a subsequent FedBizOpps amendment to this BAA.



Questions from industry regarding the Special Instruction B (announced in a subsequent FedBizOpps amendment) may be emailed to CBRN-BAA@hhs.gov no later than March 15, 2010. Submitted questions will be addressed during the March 26th Pre-Proposal Conference.



NOTE: For those who are unable to attend, please use the following dial-in information: 1-877-485-1790 Participant code # 2721294.